Trump will nominate acting CDC director Susan Monarez for the position,
White House official says
[March 25, 2025]
By SEUNG MIN KIM, AMANDA SEITZ and MIKE STOBBE
WASHINGTON (AP) —
President Donald Trump will nominate Susan Monarez, the acting director
of the U.S. Centers for Disease Control and Prevention and a longtime
federal staffer, to the permanent position, a White House official
confirmed Monday.
Trump abruptly withdrew the nomination of his first pick, David Weldon,
earlier this month.
Monarez has been serving as the CDC’s acting director since January and
came from another federal agency, the Advanced Research Projects Agency
for Health. Monarez, 50, holds a doctorate in microbiology and
immunology from the University of Wisconsin, and her postdoctoral
training was in microbiology and immunology at Stanford University.
A CDC spokesperson referred a question about Monarez to the White House.
In a social media post, Trump said that Monarez will work closely with
Health Secretary Robert F. Kennedy Jr.
“As an incredible mother and dedicated public servant, Dr. Monarez
understands the importance of protecting our children, our communities,
and our future,” Trump said in the post on Monday afternoon. “Americans
have lost confidence in the CDC due to political bias and disastrous
mismanagement.”
Earlier this month, the White House withdrew the nomination of Weldon, a
former Florida congressman, to lead the CDC. Weldon told the media his
nomination was withdrawn because “there were not enough votes to get me
confirmed.” Weldon was closely aligned with Kennedy, who for years has
been one of the nation’s leading anti-vaccine activists.
The CDC is based in Atlanta and has a core budget of more than $9
billion. It was created nearly 80 years ago to prevent the spread of
malaria in the U.S. Its mission was later expanded, and it gradually
became a global leader on infectious and chronic diseases and a go-to
source of health information.
[to top of second column]
|
 Prior to being named the CDC's
acting director earlier this year, Monarez was largely known for her
government roles in health technology and biosecurity.
She came from ARPA-H, a small agency that's also part of the U.S.
Department of Health and Human Services. ARPA-H started in 2022 to
help develop breakthrough technology for health. At that agency, she
was known for working on AI; a 2022 post on the ARPA-H LinkedIn page
described her as “the Kevin Bacon of biomedical innovation.”
Before that, she held roles at the Health Resources and Services
Administration at HHS, the White House's Office of Science and
Technology Policy and the National Security Council. She once had a
leadership position at the Department of Homeland Security and at
the Biomedical Advanced Research Projects Authority in HHS, and also
has served on a number of science advisory panels.
“She has several solid attributes: strong respect for science based
decision making, has successfully worked in government, has managed
programs in complex environments and is an expert in infectious
disease. If confirmed, I look forward to working with her,” American
Public Health Association executive director Dr. Georges Benjamin
said in an email.
In the first week of the Trump administration, she was named as the
agency's principal deputy director and was appointed the agency's
acting director until Weldon was confirmed.
Some current and former CDC employees who have spoken with The
Associated Press said in the last two months Monarez has widely been
seen as a conduit for HHS directives. They also said she hasn’t held
“all-hands” meetings at the agency and has not been a highly visible
leader.
“She has communicated almost nothing with staff,” said one current
employee, who spoke on condition of anonymity for fear of being
fired.
___
Stobbe reported from New York.
All contents © copyright 2025 Associated Press. All rights reserved |
